RO4917523 mass balance, pharmacokinetics, metabolism, and oral bioavailability study in healthy male volunteers

Open-label, single-arm trial of basimglurant in major depressive disorder (MDD) and Fragile X syndrome (FXS), sponsored by Roche. Primary endpoints: Mass balance and routes/rates of elimination of radiolabeled RO4917523, Plasma pharmacokinetics of RO4917523 and total drug-related radioactivity and 2 more. Started Jan 2012; status: active, not recruiting.